Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Chronic Lymphocytic Leukaemia: Update Bulletin # 2 [February 2019]

Product Code:
596201049
Publication Date:
February 2019
Format:
PDF
Price:
$1,315

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the chronic lymphocytic leukaemia (CLL) market, including: Roche and AbbVie announcing that a Phase III study (CLL14) investigating the combination of Venclexta/Venclyxto (venetoclax) with Gazyva (obinutuzumab) in patients with previously untreated CLL and co-existing medical conditions, met its primary endpoint; TG Therapeutics announcing updated clinical data from its Phase I/II trial of a triple combination regimen incorporating ublituximab, umbralisib, and Keytruda (pembrolizumab; Merck & Co.) in patients with relapsed/refractory CLL and Richter's transformation; as well as AstraZeneca and Acerta Pharma presenting updated results of an ongoing Phase I/II trial (ACE-CL-001) assessing Calquence (acalabrutinib) monotherapy in treatment-naïve patients with CLL.

Business Questions:

• What do KOLs think of the Phase III CLL14 trial, evaluating Venclexta plus Gazyva, meeting its primary endpoint?
• According to KOLs, what important attribute does the Venclexta/Gazyva combination have that may make it attractive to payers?
• How impressed are KOLs with the results from the Phase I/II trial, investigating the triple combination of ublituximab, umbralisib, and Keytruda in patients with relapsed/refractory CLL and Richter's transformation?
• Are there any potential advantages to the ublituximab/umbralisib/Keytruda combination compared to ublituximab/umbralisib combination?
• How do KOLs rate the safety and efficacy of Calquence (acalabrutinib) in an ongoing Phase I/II trial (ACE-CL-001) assessing Calquence monotherapy in treatment-naïve patients with CLL?
• If approved, where in the treatment paradigm will Calquence be used?





customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved